GlaxoSmithKline Plc’s chief executive Andrew Witty said that it is “too early” to quantify the impact on its financial results of an ongoing investigation by the Chinese authorities into allegations of misconduct by certain individuals in the company – an investigation that has widened in recent days to include other large pharmaceutical companies.
